Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Unusual gram positive bacteremia has been reported in non granulopenic patients receiving recombinant human interleukin-2 (IL-2) suggesting a beneficial effect of anti gram positive prophylaxis in such patients. We report here studies on granulocyte functions examined during the course of high dose IL-2 therapy (16 to 24 million IU/m2/days for 11 to 18 days) administered during a period of 35 days in 14 patients including 4 solid tumors, 5 chronic myeloid leukemias, 4 recipients of autologous bone marrow transplant (ABMT) and 1 recipient of syngeneic bone marrow transplant. Neutrophils functions were studied before IL-2 administration (d 0), after the first cycle (d 8) and after the third cycle (d 36). Nylon fiber adherence, superoxide production, random migration, phagocytosis, nitroblue tetrazolium reduction, lysozyme and elastase release were not impaired significantly throughout therapy. However N-Formyl-Methionyl-Leucyl-Phenylalanine (FMLP) stimulated chemotaxis of granulocytes, normal before therapy, was significantly impaired as early at d 8 and severely inhibited at d 36 (p less than 0.001). Three septicemia, one corynebacteria parvum septicemia and two gram-negative septicemia despite normal neutrophil counts and oxacillin or Penicillin G plus Pefloxacin prophylaxis, occurred among the 14 patients studied. Although neutrophil functions were not more depressed in transplanted patients than in the other non transplanted patients, special attention should be paid to such patients in whom delayed immune reconstitution could increase the risk of sepsis.
 ...
PMID:Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. 166 18

Pefloxacin 800 to 1200 mg daily was given for 3 to 20 days, orally or intravenously, to 84 immunocompromised patients. Five patients dropped out because of side effects and 2 for other causes. Treatment efficacy was evaluated in 77 patients, 43 men and 34 women, aged 18 to 80 years. Immunodepression resulted from malignancy in 46 patients, LAS/ARC or AIDS in 28, and from unknown causes in 3. Fifty-eight patients had documented infections (respiratory-tract infections 29, urinary-tract infections 13, septicemia 10, other 6) and 19 had a fever of unknown origin (FUO). Cure or significant improvement of symptoms was achieved in 81% of patients with documented infections and in 74% of patients with FUO. Side effects (mainly gastrointestinal disturbances and skin rash) occurred in 7 patients (8.2%), including dropouts. These results suggest that pefloxacin may be useful for the antibacterial treatment of immunodepressed patients.
 ...
PMID:Pefloxacin in the antibacterial treatment of immunodepressed patients. 219 29

Thirty two patients (16 female and 16 male), ranging in age from 13 to 80 years, were treated with pefloxacin (Abactal) at The Clinic of Infectious Diseases and Febrile Conditions. Pefloxacin was applied parenterally in 21 patients with serious infections. 15 of the cases had the signs of verified septicemia, i. e. bacteriemia; 5 patients developed purulent meningitis, i. e. meningoencephalitis; and in one patient bronchopneumonia occurred. Isolated causative agents (Staphylococcus aureus, S. epidermis and Gram-negative aerobic bacteria), were sensitive to pefloxacin. In 11 patients with enterocolitis Abactal was also included in the treatment because of the increasing occurrence of the resistance of Salmonella spp. to various chemotherapeutics and excellent "in vitro" effects of pefloxacin to those multiple-resistant species. Salmonella virchow was isolated from the stools of 6 patients. Salmonella enteritidis from 3 patients, Shigella sonnei from one, and in one case the causative agent was not identified. Pefloxacin was applied per os or parenterally in the dosage of 800-1200 mg in the period from 5-9 days. In all the patients (100%) eradication of the causative agents found in stools was done as early as the third or fourth day of the therapy. There were no adverse effects.
 ...
PMID:[Pefloxacin in the treatment of septicemia, purulent meningitis and salmonellosis]. 264 Feb 75

Thirty hospitalized patients (22 men and eight women), aged between 15 and 41 years (mean = 25.4 years), with severe proven typhoid sepsis were treated with pefloxacin at daily dose of 1200 mg, divided in three doses, intravenously for the first five days and orally for the following ten days of treatment. All patients completely recovered from infection and pathogens were eradicated after 30 days of follow-up. In none of the patients was a relapse registered during the follow-up or enteric carrier state after disease. Pefloxacin therapy was well tolerated by all patients: in five patients a mild and transient epigastric pain and in one patient a mild and transient nausea were registered. Pefloxacin is a safe and effective agent for therapy of typhoid fever.
 ...
PMID:Clinical experience with pefloxacin in the therapy of typhoid fever. 271 62

Antibiotic therapy in burn centres with highly specialized ICUs has reduced the mortality and morbidity in burn and trauma but, in spite of constantly improving supportive surgical and resuscitation methods, infection remains a major problem. Indeed, the clinical experience, as recorded in Europe and the USA, using different antimicrobial drugs and regimens, emphasizes a constantly evolving pattern of pathogenic microorganisms in the wound and in the rest of the patient's body, and their increasing chemoresistance. We report the preliminary results of 559 patients in a large controlled multicentre clinical study (mean age 41.4 +/- 17.8 years and burns covering a mean body surface area of 35.7%), with the collaboration of 13 of the 15 major Italian burn centres. The antibiotic treatment consisted of prophylactic administration of pefloxacin (800 mg i.v. OD for 4 days) for all patients as a first treatment while waiting for an antibiogram, and chemotherapy with teicoplanin (800 mg i.v. OD) together with netilmicin (300 mg i.m. OD) in one or more cycles. At random, half of the patients received thymostimulin (70 mg i.m. OD pro die for the first month and every other day thereafter until discharge from hospital). Of the bacterial pathogens involved in septic complications, 63.3% were Gram-positive (Staphylococcus spp. and Streptococcus spp.). The mortality rate was 15.5%. Pefloxacin chemoprophylaxis was successful in 19.4% of patients and cure or improvement was seen with combination chemotherapy in 66.7% of patients, mainly with only one treatment cycle. The incidence of mortality and sepsis was not significantly influenced by treatment with thymostimulin.
 ...
PMID:Antibiotic treatment of burned patients: an Italian multicentre study. 769 54

High efficacy of pefloxacin was shown in its study on albino mice with experimental infections such as sepsis, pneumonia and peritonitis. In the effective doses administered orally the drug rapidly arrested the clinical signs of the diseases and provided the sanation of the organs and tissues. The broad antibacterial spectrum of pefloxacin substantiated its efficacy in the treatment of purulent septic processes due to gram-negative and gram-positive pathogens, as well as in the treatment of mixed infections. It is a drug with prolonged action which was confirmed with its prophylactic use. Pefloxacin was efficient in the treatment of infections of various severity.
 ...
PMID:[Chemotherapeutic effectiveness of pefloxacin in experimental infections]. 773 83

Twenty four women with postoperative sepsis following gynaecological surgery were recruited into a study designed to determine the efficacy of Pefloxacin. With the standard oral dose of Pefloxacin, clinical cure or improvement occurred in 98% of the patients. In-vitro, 90% of bacterial isolates were sensitive to Pefloxacin. No adverse effect was encountered in any of the patients. We concluded that Pefloxacin is effective in the treatment of postoperative bacterial infections following gynaecological surgery.
 ...
PMID:Efficacy of pefloxacin in the treatment of postoperative sepsis in gynaecology. 1120 20